The genesis of Zelboraf: Targeting mutant B-Raf in melanoma

Journal of Cell Biology

Volumn 199, Issue 1, 2012, Pages 15-19

  Davis, Matthew J ^a   Schlessinger, Joseph ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACARBAZINE; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MUTANT PROTEIN; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; PROTEIN TYROSINE KINASE INHIBITOR; RAS PROTEIN; SORAFENIB; VEMURAFENIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CRYSTAL STRUCTURE; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG RESEARCH; DRUG TARGETING; ENZYME ACTIVATION; ENZYME STRUCTURE; EUROPEAN UNION; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN CELL; KERATOACANTHOMA; KIDNEY CANCER; MELANOMA; MELANOMA CELL; METASTASIS; MOLECULARLY TARGETED THERAPY; MOUSE; MUTATION; NONHUMAN; ONCOGENE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; UNITED STATES;

ANTINEOPLASTIC AGENTS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INDOLES; MELANOMA; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 84869109771     PISSN: 00219525     EISSN: 15408140     Source Type: Journal    
DOI: 10.1083/jcb.201205167     Document Type: Article

References (28)

1. Bollag, G., P. Hirth, J. Tsai, J. Zhang, P.N. Ibrahim, H. Cho, W. Spevak, C. Zhang, Y. Zhang, G. Habets, et al. 2010. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 467:596-599. http://dx.doi.org/10.1038/nature09454
2. Card, G.L., L. Blasdel, B.P. England, C. Zhang, Y. Suzuki, S. Gillette, D. Fong, P.N. Ibrahim, D.R. Artis, G. Bollag, et al. 2005. A family of phosphodiesterase inhibitors discovered by cocrystallography and scaf- fold-based drug design. Nat. Biotechnol. 23:201-207. http://dx.doi.org/10.1038/nbt1059
3. Chapman, P.B., A. Hauschild, C. Robert, J.B. Haanen, P. Ascierto, J. Larkin, R. Dummer, C. Garbe, A. Testori, M. Maio, et al. BRIM-3 Study Group. 2011. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364:2507-2516. http://dx.doi.org/10.1056/NEJMoa1103782
4. Cobb, M.H. 1999. MAP kinase pathways. Prog. Biophys. Mol. Biol. 71:479- 500. http://dx.doi.org/10.1016/S0079-6107(98)00056-X
5. Coll, J., M. Righi, C. Taisne, C. Dissous, A. Gegonne, and D. Stehelin. 1983. Molecular cloning of the avian acute transforming retrovirus MH2 re- veals a novel cell-derived sequence (v-mil) in addition to the myc onco- gene. EMBO J. 2:2189-2194.
6. Davies, H., G.R. Bignell, C. Cox, P. Stephens, S. Edkins, S. Clegg, J. Teague, H. Woffendin, M.J. Garnett, W. Bottomley, et al. 2002. Mutations of the BRAF gene in human cancer. Nature. 417:949-954. http://dx.doi.org/10.1038/nature00766
7. Dhillon, A.S., S. Hagan, O. Rath, and W. Kolch. 2007. MAP kinase signal- ling pathways in cancer. Oncogene. 26:3279-3290. http://dx.doi.org/10.1038/sj.onc.1210421
8. Escudier, B., T. Eisen, W.M. Stadler, C. Szczylik, S. Oudard, M. Siebels, S. Negrier, C. Chevreau, E. Solska, A.A. Desai, et al. TARGET Study Group. 2007. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356:125-134. http://dx.doi.org/10.1056/NEJMoa060655
9. Flaherty, K.T., I. Puzanov, K.B. Kim, A. Ribas, G.A. McArthur, J.A. Sosman, P.J. O'Dwyer, R.J. Lee, J.F. Grippo, K. Nolop, and P.B. Chapman. 2010. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363:809-819. http://dx.doi.org/10.1056/NEJMoa1002011
10. Futreal, P.A., L. Coin, M. Marshall, T. Down, T. Hubbard, R. Wooster, N. Rahman, and M.R. Stratton. 2004. A census of human cancer genes. Nat. Rev. Cancer. 4:177-183. http://dx.doi.org/10.1038/nrc1299
11. Hatzivassiliou, G., K. Song, I. Yen, B.J. Brandhuber, D.J. Anderson, R. Alvarado, M.J. Ludlam, D. Stokoe, S.L. Gloor, G. Vigers, et al. 2010. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature. 464:431-435. http://dx.doi.org/10.1038/nature08833
12. Huleihel, M., M. Goldsborough, J. Cleveland, M. Gunnell, T. Bonner, and U.R. Rapp. 1986. Characterization of murine A-raf, a new oncogene related to the v-raf oncogene. Mol. Cell. Biol. 6:2655-2662.
13. Ikawa, S., M. Fukui, Y. Ueyama, N. Tamaoki, T. Yamamoto, and K. Toyoshima. 1988. B-raf, a new member of the raf family, is activated by DNA rear- rangement. Mol. Cell. Biol. 8:2651-2654.
14. Lowenstein, E.J., R.J. Daly, A.G. Batzer, W. Li, B. Margolis, R. Lammers, A. Ullrich, E.Y. Skolnik, D. Bar-Sagi, and J. Schlessinger. 1992. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell. 70:431-442. http://dx.doi.org/10.1016/0092-8674(92)90167-B
15. Manning, G., D.B. Whyte, R. Martinez, T. Hunter, and S. Sudarsanam. 2002. The protein kinase complement of the human genome. Science. 298:1912- 1934. http://dx.doi.org/10.1126/science.1075762
16. Nazarian, R., H. Shi, Q. Wang, X. Kong, R.C. Koya, H. Lee, Z. Chen, M.K. Lee, N. Attar, H. Sazegar, et al. 2010. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 468:973-977. http://dx.doi.org/10.1038/nature09626
17. Poulikakos, P.I., C. Zhang, G. Bollag, K.M. Shokat, and N. Rosen. 2010. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild- type BRAF. Nature. 464:427-430. http://dx.doi.org/10.1038/nature08902
18. Poulikakos, P.I., Y. Persaud, M. Janakiraman, X. Kong, C. Ng, G. Moriceau, H. Shi, M. Atefi, B. Titz, M.T. Gabay, et al. 2011. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 480:387-390. http://dx.doi.org/10.1038/nature10662
19. Rapp, U.R., M.D. Goldsborough, G.E. Mark, T.I. Bonner, J. Groffen, F.H. Reynolds Jr., and J.R. Stephenson. 1983. Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus. Proc. Natl. Acad. Sci. USA. 80:4218-4222. http://dx.doi.org/10.1073/pnas.80.14.4218
20. Shi, H., G. Moriceau, X. Kong, M.K. Lee, H. Lee, R.C. Koya, C. Ng, T. Chodon, R.A. Scolyer, K.B. Dahlman, et al. 2012. Melanoma whole- exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun. 3:724. http://dx.doi.org/10.1038/ncomms1727
21. Solit, D.B., L.A. Garraway, C.A. Pratilas, A. Sawai, G. Getz, A. Basso, Q. Ye, J.M. Lobo, Y. She, I. Osman, et al. 2006. BRAF mutation predicts sen- sitivity to MEK inhibition. Nature. 439:358-362. http://dx.doi.org/10.1038/nature04304
22. Sosman, J.A., K.B. Kim, L. Schuchter, R. Gonzalez, A.C. Pavlick, J.S. Weber, G.A. McArthur, T.E. Hutson, S.J. Moschos, K.T. Flaherty, et al. 2012. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 366:707-714. http://dx.doi.org/10.1056/NEJMoa1112302
23. Su, F., A. Viros, C. Milagre, K. Trunzer, G. Bollag, O. Spleiss, J.S. Reis-Filho, X. Kong, R.C. Koya, K.T. Flaherty, et al. 2012. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N. Engl. J. Med. 366:207-215. http://dx.doi.org/10.1056/NEJMoa1105358
24. Tol, J., I.D. Nagtegaal, and C.J. Punt. 2009. BRAF mutation in metastatic colorectal cancer. N. Engl. J. Med. 361:98-99. http://dx.doi.org/10.1056/NEJMc0904160
25. Tsai, J., J.T. Lee, W. Wang, J. Zhang, H. Cho, S. Mamo, R. Bremer, S. Gillette, J. Kong, N.K. Haass, et al. 2008. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl. Acad. Sci. USA. 105:3041-3046. http://dx.doi.org/10.1073/pnas.0711741105
26. Villanueva, J., A. Vultur, J.T. Lee, R. Somasundaram, M. Fukunaga-Kalabis, A.K. Cipolla, B. Wubbenhorst, X. Xu, P.A. Gimotty, D. Kee, et al. 2010. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 18:683-695. http://dx.doi.org/10.1016/j.ccr.2010.11.023
27. Wagle, N., C. Emery, M.F. Berger, M.J. Davis, A. Sawyer, P. Pochanard, S.M. Kehoe, C.M. Johannessen, L.E. Macconaill, W.C. Hahn, et al. 2011. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J. Clin. Oncol. 29:3085-3096. http://dx.doi.org/10.1200/JCO.2010.33.2312
28. Waitz, R., S.B. Solomon, E.N. Petre, A.E. Trumble, M. Fassò, L. Norton, and J.P. Allison. 2012. Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Res. 72:430-439. http://dx.doi.org/10.1158/0008-5472.CAN-11-1782